300294 博雅生物
交易中 08-05 13:37:54
资讯
新帖
简况
博雅生物:持续推进“引进来、走出去、强合作”的国际化战略
证券之星 · 07-31
博雅生物:持续推进“引进来、走出去、强合作”的国际化战略
股市必读:博雅生物(300294)7月28日董秘有最新回复
证券之星 · 07-29
股市必读:博雅生物(300294)7月28日董秘有最新回复
博雅生物:公司2026年7月20日股东人数为32,229户
证券之星 · 07-28
博雅生物:公司2026年7月20日股东人数为32,229户
股市必读:博雅生物(300294)7月21日董秘有最新回复
证券之星 · 07-22
股市必读:博雅生物(300294)7月21日董秘有最新回复
博雅生物:坚持长期主义,聚焦主业
证券之星 · 07-21
博雅生物:坚持长期主义,聚焦主业
博雅生物(300294.SZ):人血管性血友病因子工艺升级后重新获批临床试验
智通财经 · 07-20
博雅生物(300294.SZ):人血管性血友病因子工艺升级后重新获批临床试验
股市必读:博雅生物(300294)7月17日董秘有最新回复
证券之星 · 07-20
股市必读:博雅生物(300294)7月17日董秘有最新回复
博雅生物:采用低温乙醇法联合层析纯化工艺生产10%静丙
证券之星 · 07-17
博雅生物:采用低温乙醇法联合层析纯化工艺生产10%静丙
股市必读:博雅生物(300294)7月14日董秘有最新回复
证券之星 · 07-15
股市必读:博雅生物(300294)7月14日董秘有最新回复
博雅生物:持续推进“引进来、走出去、强合作”的国际化战略
证券之星 · 07-14
博雅生物:持续推进“引进来、走出去、强合作”的国际化战略
博雅生物:公司结合整体产能规划、采浆量以及各产线设备运行、工艺调试等实际情况统筹安排生产计划,保障生产运营平稳有序
证券之星 · 07-14
博雅生物:公司结合整体产能规划、采浆量以及各产线设备运行、工艺调试等实际情况统筹安排生产计划,保障生产运营平稳有序
博雅生物:构建科学、持续、稳定的股东回报机制
证券之星 · 07-14
博雅生物:构建科学、持续、稳定的股东回报机制
博雅生物:公司一直坚持长期主义
证券之星 · 07-14
博雅生物:公司一直坚持长期主义
博雅生物:内生式发展和投资并购均是公司达成战略目标的途径
证券之星 · 07-09
博雅生物:内生式发展和投资并购均是公司达成战略目标的途径
股市必读:博雅生物(300294)7月8日董秘有最新回复
证券之星 · 07-09
股市必读:博雅生物(300294)7月8日董秘有最新回复
博雅生物:成为世界一流血液制品企业
证券之星 · 07-08
博雅生物:成为世界一流血液制品企业
博雅生物:坚持长期主义,聚焦主业提升经营质量与盈利能力
证券之星 · 06-30
博雅生物:坚持长期主义,聚焦主业提升经营质量与盈利能力
博雅生物:持续深耕血液制品主业
证券之星 · 06-30
博雅生物:持续深耕血液制品主业
博雅生物(300294)披露转让南京新百药业100%股权进展暨完成工商变更登记公告,6月25日股价下跌2.99%
证券之星 · 06-25
博雅生物(300294)披露转让南京新百药业100%股权进展暨完成工商变更登记公告,6月25日股价下跌2.99%
博雅生物:紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素
证券之星 · 06-24
博雅生物:紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素
暂无数据
公司概况
公司名称:
华润博雅生物制药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-03-08
主营业务:
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格:
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":15.62,"timestamp":1785908274000,"preClose":15.83,"halted":0,"volume":3490000,"delay":0,"changeRate":-0.0133,"floatShares":504000000,"shares":504000000,"eps":0.0069,"marketStatus":"交易中","change":-0.21,"latestTime":"08-05 13:37:54","open":15.8,"high":15.86,"low":15.58,"amount":54741400,"amplitude":0.0177,"askPrice":15.63,"askSize":169,"bidPrice":15.62,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.0069,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1785913200000},"marketStatusCode":2,"adr":0,"adjPreClose":15.83,"symbolType":"stock","openAndCloseTimeList":[[1785893400000,1785900600000],[1785906000000,1785913200000]],"highLimit":17.41,"lowLimit":14.25,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.07,"roa":"--","peRate":2263.768116,"roe":"0.41%","epsLYR":0.22,"committee":0.4112,"marketValue":7876000000,"turnoverRate":0.0069,"status":1,"floatMarketCap":7876000000},"requestUrl":"/m/hq/s/300294/tweets","defaultTab":"tweets","newsList":[{"id":"2655356292","title":"博雅生物:持续推进“引进来、走出去、强合作”的国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655356292?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:36","pubTimestamp":1785486979,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问:东南亚注册门槛偏低,依托华人渠道发挥价格优势,博雅生物下半年有希望出口东南亚市场吗?博雅生物回复:您好,感谢您对本公司的关注。公司持续推进“引进来、走出去、强合作”的国际化战略,有序推进国际合作。公司经营情况及财务状况等信息,请以公司公告为准。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100027356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884941","title":"股市必读:博雅生物(300294)7月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655884941?lang=zh_cn&edition=full","pubTime":"2026-07-29 02:23","pubTimestamp":1785262990,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘,博雅生物报收于14.78元,上涨0.34%,换手率0.93%,成交量4.68万手,成交额6863.15万元。董秘最新回复投资者: 贵公司股价长期下跌,且较同行企业下跌幅度大,反弹幅度小,公司有从资金方面提振股价的措施吗?博雅生物作为央企子公司是否通过股东增持、股份回购等方式,向市场传递积极信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900001481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654070944","title":"博雅生物:公司2026年7月20日股东人数为32,229户","url":"https://stock-news.laohu8.com/highlight/detail?id=2654070944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654070944?lang=zh_cn&edition=full","pubTime":"2026-07-28 17:21","pubTimestamp":1785230469,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问:公司最近的股东数量是多少?博雅生物回复:您好,感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据,公司2026年7月20日含信用账户合并名册的股东人数为32,229户。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800028056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653202770","title":"股市必读:博雅生物(300294)7月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653202770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653202770?lang=zh_cn&edition=full","pubTime":"2026-07-22 02:10","pubTimestamp":1784657453,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘,博雅生物报收于15.4元,下跌2.35%,换手率1.66%,成交量8.36万手,成交额1.3亿元。董秘最新回复投资者: 近期两大央企宣布增持中央企业股票,坚决维护资本市场平稳运行。博雅生物作为国有企业,管理层是否坚决维护公司市值,看好企业自身发展?当日关注点交易信息汇总:7月21日主力资金净流出318.94万元,游资资金净流入600.86万元,散户资金净流出281.92万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200002675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653927199","title":"博雅生物:坚持长期主义,聚焦主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2653927199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653927199?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:00","pubTimestamp":1784631650,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物07月21日在投资者关系平台上答复投资者关心的问题。博雅生物作为国有企业,管理层是否坚决维护公司市值,看好企业自身发展?公司一直坚持长期主义,围绕战略目标,聚焦主业,强化核心竞争力,结合政策环境、市场环境等制定适合公司发展的经营策略,努力做好经营管理,提升经营质量与盈利能力,促进公司健康可持续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100037850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652295236","title":"博雅生物(300294.SZ):人血管性血友病因子工艺升级后重新获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2652295236","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652295236?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:22","pubTimestamp":1784535724,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博雅生物(300294.SZ)发布公告,近日,公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发的人血管性血友病因子《药物临床试验批准通知书》(通知书编号:2026LP02173)。本次获批为该产品完成核心生产工艺升级后的重新申报获批,不属于全新首次申报。本次人血管性血友病因子工艺升级后重新获批临床试验,是公司对该产品核心生产技术的重要优化,为临床试验顺利推进筑牢基础。本次获批临床试验事项将进一步激发研发团队创新积极性,完善公司在罕见出血性疾病领域的产品管线布局,为丰富血液制品产品线、强化核心市场竞争力提供有力支撑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0197","BK0046","BK0239","IBBQ","300294","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652252257","title":"股市必读:博雅生物(300294)7月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2652252257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652252257?lang=zh_cn&edition=full","pubTime":"2026-07-20 01:24","pubTimestamp":1784481852,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,博雅生物报收于15.66元,下跌3.39%,换手率1.96%,成交量9.86万手,成交额1.57亿元。国内血液制品行业主流基础工艺为低温乙醇法,层析工艺主要用于后端精制环节以提升产品纯度。公司目前采用低温乙醇法联合层析纯化工艺生产10%静丙。交易信息汇总资金流向7月17日主力资金净流出1340.32万元,占总成交额0.0%;游资资金净流出663.21万元,占总成交额0.0%;散户资金净流入2003.53万元,占总成交额0.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000000694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652403711","title":"博雅生物:采用低温乙醇法联合层析纯化工艺生产10%静丙","url":"https://stock-news.laohu8.com/highlight/detail?id=2652403711","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652403711?lang=zh_cn&edition=full","pubTime":"2026-07-17 15:57","pubTimestamp":1784275031,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问:公司的技术路线什么时候能从\"低温乙醇\"切换到\"层析主导\"。博雅生物回复:您好,感谢您对本公司的关注。国内血液制品行业主流基础工艺为低温乙醇法,层析工艺主要用于后端精制环节以提升产品纯度。公司目前采用低温乙醇法(改良Cohn6法)联合层析纯化工艺生产10%静丙。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700028413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651148322","title":"股市必读:博雅生物(300294)7月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651148322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651148322?lang=zh_cn&edition=full","pubTime":"2026-07-15 02:12","pubTimestamp":1784052734,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘,博雅生物报收于15.12元,上涨2.72%,换手率1.9%,成交量9.6万手,成交额1.45亿元。董秘最新回复投资者: 贵公司近几年股价在血制品行业里跌幅最大,华润管理是否存在巨大漏洞?经查询中国证券登记结算有限责任公司的数据,公司2026年7月10日含信用账户合并名册的股东人数为31,020户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500002497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651176895","title":"博雅生物:持续推进“引进来、走出去、强合作”的国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2651176895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651176895?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:57","pubTimestamp":1784019441,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问:今年博雅生物出海取得啥成绩请介绍下。博雅生物回复:您好,感谢您对本公司的关注。公司持续推进“引进来、走出去、强合作”的国际化战略,多元探索、多路并进。系统性加强全产品线在非法规及半法规市场的国际贸易注册工作,多途径、多渠道开展国际业务。具体情况请参阅公司公告。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400031713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651763121","title":"博雅生物:公司结合整体产能规划、采浆量以及各产线设备运行、工艺调试等实际情况统筹安排生产计划,保障生产运营平稳有序","url":"https://stock-news.laohu8.com/highlight/detail?id=2651763121","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651763121?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:57","pubTimestamp":1784019439,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,在江西省药品检验检测研究院看博雅的批签发数据,静丙生产到批签发周期6个月,其他品种、同行业的静丙生产批签发周期均约3个月,能说明一下博雅的静丙为什么需要6个月吗?博雅生物回复:您好,感谢您对本公司的关注。公司结合整体产能规划、采浆量以及各产线设备运行、工艺调试等实际情况统筹安排生产计划,保障生产运营平稳有序。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400031709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","BK0046","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651082175","title":"博雅生物:构建科学、持续、稳定的股东回报机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2651082175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651082175?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:57","pubTimestamp":1784019439,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物07月14日在投资者关系平台上答复投资者关心的问题。公司将结合经营实际,综合考量当期及未来盈利水平、现金流状况、行业发展阶段、项目投资需求等因素,兼顾股东合理投资回报与公司长期可持续发展,构建科学、持续、稳定的股东回报机制,保障利润分配政策保持连续性与稳定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400031711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0197","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651038175","title":"博雅生物:公司一直坚持长期主义","url":"https://stock-news.laohu8.com/highlight/detail?id=2651038175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651038175?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:54","pubTimestamp":1784019277,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司近几年股价在血制品行业里跌幅最大,华润管理是否存在巨大漏洞?博雅生物回复:您好,感谢您对本公司的关注。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司一直坚持长期主义,紧紧围绕战略目标,聚焦主业,强化核心竞争力,结合政策环境、市场环境等制定适合公司发展的经营策略,努力做好经营管理,提升经营质量与盈利能力,促进公司健康可持续发展。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400031609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924141","title":"博雅生物:内生式发展和投资并购均是公司达成战略目标的途径","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650924141?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:48","pubTimestamp":1783601305,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问:管理层,下半年有考虑通过加上投资并购来不断提升公司的市场竞争力吗?博雅生物回复:您好,感谢您对公司的关注。公司始终围绕“成为世界一流血液制品企业”的战略愿景开展经营活动,内生式发展和投资并购均是公司达成战略目标的途径。如公司有相关计划,将根据证券法规及时履行信息披露义务。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900040342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650918831","title":"股市必读:博雅生物(300294)7月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2650918831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650918831?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:34","pubTimestamp":1783532050,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,博雅生物报收于14.59元,下跌0.41%,换手率0.93%,成交量4.68万手,成交额6844.79万元。董秘最新回复投资者: 请问管理层下半年博雅生物投资价值在哪些地方?至目前,公司采浆量增长稳定。交易信息汇总资金流向7月8日主力资金净流出718.66万元;游资资金净流入252.64万元;散户资金净流入466.02万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649660639","title":"博雅生物:成为世界一流血液制品企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2649660639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649660639?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:00","pubTimestamp":1783497635,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问:请问管理层下半年博雅生物投资价值在哪些地方?博雅生物回复:您好,感谢您对公司的关注。公司始终围绕“成为世界一流血液制品企业”的战略愿景开展经营活动。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800026771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0197","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535550","title":"博雅生物:坚持长期主义,聚焦主业提升经营质量与盈利能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647535550?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:06","pubTimestamp":1782806788,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问:博雅生物股价已跌破每股净资产,市值马上不足70亿,请问公司管理层是否有预案和对策应对这样的不利局面博雅生物回复:您好,感谢您对本公司的关注。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司一直坚持长期主义,紧紧围绕战略目标,聚焦主业,强化核心竞争力,结合政策环境、市场环境等制定适合公司发展的经营策略,努力做好经营管理,提升经营质量与盈利能力,促进公司健康可持续发展。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535817","title":"博雅生物:持续深耕血液制品主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535817","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647535817?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:03","pubTimestamp":1782806600,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问:这场寒冬,既是挑战也是机遇,它会淘汰那些只会躺着赚钱的惰性企业,也会催生具备产品创新能力和精细化管理水平的优质公司。请问博雅如何找到新的增长引擎?博雅生物回复:您好,感谢您对本公司的关注。公司将始终围绕战略目标,持续深耕血液制品主业,多措并举夯实发展根基,聚焦血浆、营销、研发、国际化等核心业务领域,持续蓄力厚植增长动能,提升综合竞争力。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000027270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","300294","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646809465","title":"博雅生物(300294)披露转让南京新百药业100%股权进展暨完成工商变更登记公告,6月25日股价下跌2.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646809465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646809465?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:35","pubTimestamp":1782398118,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘,博雅生物报收于14.59元,较前一交易日下跌2.99%,最新总市值为73.57亿元。近日,博雅生物披露《关于转让南京新百药业有限公司100%股权进展暨完成工商变更登记的公告》。公告显示,华润博雅生物制药集团股份有限公司于2026年4月23日召开董事会,审议通过将南京新百药业有限公司100%股权转让给华润双鹤药业股份有限公司的议案,交易金额为23,545.62万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300294","600682","BK0093","BK0196","BK0046","BK0113","BK0239","BK0209","BK0060","BK0197","BK0183","BK0042","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645860891","title":"博雅生物:紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素","url":"https://stock-news.laohu8.com/highlight/detail?id=2645860891","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645860891?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:07","pubTimestamp":1782284835,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问:华润入主博雅这些年来,董秘觉得企业在维护投资者信心方面做得怎么样?还有哪些可以改进的?博雅生物回复:您好,非常感谢您对本公司的关注。面对行业周期下行,公司上下树立危机意识、凝聚战略共识,紧紧围绕“技术、人才、品牌、效率、机制”五大核心要素,苦练内功,打造五大能力,以提升核心竞争力!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400022176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300294"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785908278619,"stockEarnings":[{"period":"1week","weight":0.071},{"period":"1month","weight":0.0456},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.2917},{"period":"1year","weight":-0.4149},{"period":"ytd","weight":-0.2964}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":-0.0547},{"period":"3month","weight":-0.0812},{"period":"6month","weight":-0.0622},{"period":"1year","weight":0.0667},{"period":"ytd","weight":-0.0369}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32229人(较上一季度增加3.90%)","perCapita":"15645股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}